Opiant Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference

SANTA MONICA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that Roger Crystal, M.D., Opiant’s Chief Executive Officer, will provide a corporate update at the 18^th Annual Needham Healthcare Conference, being held April 9-10 in New York City.

Opiant Presentation Details

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing medicines for addictions and drug overdose. NIDA, a division of the National Institutes of Health, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Opiant's first drug overdose product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by its licensee, Adapt Pharmaceuticals, now owned by Emergent BioSolutions, Inc. For more information visit: www.opiant.com.

CONTACTS:

For Investor Relations:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
(617) 535-7746

For Media Inquiries:
Julie Normart
W2O Group
[email protected]
(415) 946-1087

You May Also Be Interested In

• Needham Starts Faeth Therapeutics (FTH) at Buy
• App Development Costs Drop From $200,000 to Near $50,000 as Chop Dawg Pairs AI-Accelerated Engineering With 18 Years of Discipline
• Norton Manx R Earns Landmark International Design Excellence Award for Reimagining the Superbike